Adverse reactions to co-trimoxazole in HIV infection

Area of Science:

• Pharmacology
• Immunology
• Infectious Diseases

Background:

• Co-trimoxazole is frequently associated with side-effects in patients with Human Immunodeficiency Virus (HIV).
• The precise mechanisms underlying this increased susceptibility remain unclear.
• Existing data on plasma concentrations of co-trimoxazole's parent compounds are inconclusive.

Purpose of the Study:

• To investigate the underlying cause of heightened co-trimoxazole-related adverse reactions in HIV-positive individuals.
• To identify the specific metabolites responsible for these adverse events.

Main Methods:

• Review of existing literature on co-trimoxazole metabolism and adverse reactions.
• Analysis of data concerning plasma concentrations of parent drugs.
• Evaluation of the role of glutathione deficiency in HIV patients.

Main Results:

• Evidence suggests that hydroxylamine derivatives of sulfamethoxazole are the reactive metabolites causing adverse reactions.
• HIV-positive individuals exhibit systemic glutathione deficiency.
• This deficiency reduces the capacity to neutralize toxic metabolites, leading to increased exposure.

Conclusions:

• Systemic glutathione deficiency in HIV patients impairs the detoxification of reactive sulfamethoxazole metabolites.
• This impaired detoxification pathway explains the increased frequency of adverse reactions to co-trimoxazole in this population.
• Targeting glutathione levels or enhancing detoxification pathways may mitigate co-trimoxazole toxicity in HIV patients.